missing translation for 'onlineSavingsMsg'
Learn More

CD262 (DR5) Monoclonal Antibody (DJR2-2 (2-6)), eBioscience™, Invitrogen™

Mouse Monoclonal Antibody

Brand:  Affymetrix eBioscience 14-9909-80

Code : Z2

Additional Details : Weight : 0.01000kg

 View more versions of this product

Product Code. 15268227

This item is currently unavailable or has been discontinued.
View the product page for possible alternatives.
View alternative products »


Description

Description

Description: The DJR2-2 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2, and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: This DJR2-2 (a.k.a. 2-6) antibody has been reported for use in flow cytometric analysis and western blotting. Applications Tested: The DJR2-2 (a.k.a. 2-6) antibody has been tested by flow cytometric analysis of human DR5-transfected cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
Specifications

Specifications

CD262 (DR5)
Monoclonal
0.5 mg/mL
PBS with 0.09% sodium azide; pH 7.2
O14763
TNFRSF10B
Affinity chromatography
RUO
8795
4° C
Liquid
Flow Cytometry, Western Blot
DJR2-2 (2-6)
Unconjugated
TNFRSF10B
apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9
Mouse
25 μg
Primary
Human
Antibody
IgG1 κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

For Research Use Only.